2024-10-18 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**Company Overview:** Merck & Co Inc is a leading pharmaceutical company known for its diverse portfolio of prescription medicines, vaccines, and animal health products. 

**Performance Analysis:**

**1. Rate of Return vs S&P 500 (VOO):**
* **Cumulative Return:** MRK (71.56%) vs. S&P 500 (136.93%)
* **Divergence:** The current divergence between MRK and the S&P 500 is -65.37%. This means MRK has underperformed the S&P 500 by 65.37%. The relative divergence, which considers the historical range of divergence, is 19.59%, indicating that the current underperformance is within the typical range of historical divergence between the two assets.

**2. Recent Price Movement:**
* **Closing Price:** $110.42
* **5-Day Moving Average:** $110.17
* **20-Day Moving Average:** $112.26
* **60-Day Moving Average:** $115.09

**3. Technical Indicators:**
* **RSI (Relative Strength Index):** 40.4 -  This suggests the stock is currently in a neutral zone, neither overbought nor oversold.
* **PPO (Percentage Price Oscillator):** 0.01 - A near-zero PPO value indicates that the price momentum is relatively weak and the stock is likely consolidating.
* **Delta_Previous_Relative_Divergence:** -19.27 - The negative value indicates a short-term downward trend in the stock's performance compared to the benchmark. 
* **Expected Return:** 0.0% - The model predicts no significant outperformance compared to the S&P 500 over the next 5 years.

**4. Recent Earnings and Outlook:**
* **Latest Earnings:** 
| Date | EPS | Revenue |
|---|---|---|
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2023-08-07 | -2.35 | 15.04 B$ |
| 2024-08-05 | -2.35 | 15.04 B$ |

* **Analysis:** While the most recent earnings (2024-08-05) beat analysts' estimates, the overall trend shows a slight decrease in revenue and inconsistent earnings performance.

**5. News and Recent Issues:**
* **Recent Market Outlook:**
    * The recent market outlook for MRK is mixed. Some analysts believe the company's strong product pipeline and consistent performance will drive future growth. However, others are concerned about potential competition and the impact of generic drug entry on the market.
* **Analyst Opinions:**
    * While analysts generally hold a "hold" rating on MRK, some believe the stock could be a good value investment in the long term. 
* **Performance Highlights:**
    * MRK's stock performance has been relatively stable in the past year. However, the company faces challenges from competition and a shift towards biosimilar drugs.

**6. Conclusion:**
* MRK has underperformed the S&P 500 in the past but the relative divergence indicates that it is within a typical range. 
* The current price movement suggests a period of consolidation with weak momentum.
* While recent earnings were positive, the overall trend shows inconsistent performance and challenges in the pharmaceutical market.
* Analysts remain optimistic about the long-term prospects of MRK, but investors should carefully consider the potential risks before investing.

**7. Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Consult with a qualified financial professional before making any investment decisions.